HomeCompareLBPH vs ORCC

LBPH vs ORCC: Dividend Comparison 2026

LBPH yields 3.33% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBPH wins by $3.4K in total portfolio value· pulled ahead in Year 3
10 years
LBPH
LBPH
● Live price
3.33%
Share price
$59.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.8K
Annual income
$413.26
Full LBPH calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — LBPH vs ORCC

📍 LBPH pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBPHORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBPH + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBPH pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBPH
Annual income on $10K today (after 15% tax)
$283.43/yr
After 10yr DRIP, annual income (after tax)
$351.27/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, LBPH beats the other by $350.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBPH + ORCC for your $10,000?

LBPH: 50%ORCC: 50%
100% ORCC50/50100% LBPH
Portfolio after 10yr
$23.1K
Annual income
$207.15/yr
Blended yield
0.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

LBPH
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
Price Target
$61.00
+1.7% upside vs current
Range: $16.00 — $90.00
Altman Z
63.6
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBPH buys
0
ORCC buys
0
No recent congressional trades found for LBPH or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBPHORCC
Forward yield3.33%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$24.8K$21.4K
Annual income after 10y$413.26$1.04
Total dividends collected$3.8K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$61.00$16.00

Year-by-year: LBPH vs ORCC ($10,000, DRIP)

YearLBPH PortfolioLBPH Income/yrORCC PortfolioORCC Income/yrGap
1$11,033$333.44$11,190$489.61$157.00ORCC
2$12,150$343.84$12,229$256.01$79.00ORCC
3← crossover$13,354$353.85$13,216$130.74+$138.00LBPH
4$14,652$363.48$14,207$66.02+$445.00LBPH
5$16,051$372.73$15,234$33.17+$817.00LBPH
6$17,556$381.59$16,317$16.62+$1.2KLBPH
7$19,175$390.07$17,468$8.32+$1.7KLBPH
8$20,915$398.17$18,695$4.16+$2.2KLBPH
9$22,785$405.89$20,006$2.08+$2.8KLBPH
10$24,793$413.26$21,407$1.04+$3.4KLBPH

LBPH vs ORCC: Complete Analysis 2026

LBPHStock

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Full LBPH Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this LBPH vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBPH vs SCHDLBPH vs JEPILBPH vs OLBPH vs KOLBPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.